Trials / Not Yet Recruiting
Not Yet RecruitingNCT07341828
A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy
An Exploratory Clinical Study of Anti-CD20/B-cell Maturation Antigen(BCMA) Chimeric Antigen Receptor Autologous T Cell Product (C-CAR168) in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Huashan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with central nervous system autoimmune diseases refractory to standard therapy
Conditions
- Multiple Sclerosis (MS)
- Neuromyelitis Optica Spectrum Disorders (NMOSD)
- Autoimmune Encephalitis
- Stiff Person Syndrome
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CD20/BCMA-directed CAR-T cells | Autologous 2nd generation CD20/BCMA-directed CAR-T cells, single infusion intravenously |
Timeline
- Start date
- 2026-02-01
- Primary completion
- 2027-06-01
- Completion
- 2029-02-01
- First posted
- 2026-01-14
- Last updated
- 2026-01-15
Source: ClinicalTrials.gov record NCT07341828. Inclusion in this directory is not an endorsement.